Siegfried Janz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Siegfried Janz has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Alexander L. Kovalchuk
Laboratory of Genetics, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA
3 shared publicationsAllen E. Coleman
3 shared publicationsJoong Su Kim
Cell Signaling Technology Inc., Beverly, Massachusetts, USA. 2Laboratory of Genetics, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA. 3University of Minnesota, Minneapolis, Minnesota, USA
3 shared publications- Arthur L Shaffer
Metabolism Branch, CCR, NCI, NIH, Bethesda, MD, USA
2 shared publications Georg-Wilhelm Bornkamm
Laboratory of Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
2 shared publicationsKlaus Felix
Laboratory of Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
2 shared publications
Latest Publications
- Open Access
- 1 July 2008
- Published by Oxford University Press (OUP) in JNCI Monographs
- Vol. 2008 (39) , 37-40
Genetic and Environmental Cofactors of Myc Translocations in Plasma Cell Tumor Development in Mice
Peritoneal plasmacytomagenesis in inbred BALB/c mice affords an experimental model system for the study of the mechanism by which naturally occurring Myc (c-myc) translocations collaborate with host susceptibility factors and environmental influences in tumor development. Mouse plasmacytoma is initiated in ∼80% of cases by a balanced chromosomal T(12;15)(Igh-Myc) translocation that results in a mode of Myc deregulation that renders the survival and outgrowth of the translocation-bearing tumor precursor exquisitely dependent upon factors provided by sustained inflammation (IL-6) and gut flora microbes. Tumor susceptibility genes of BALB/c, such as weak efficiency alleles of genes encoding p16Ink4a and Frap (mTOR), are also required for plasmacytoma, although the pathways linking these genes with deregulated Myc and the environment have not yet been elucidated. The findings in mouse plasmacytoma may be relevant for hematopoietic neoplasms in human beings, in which leukemia- and lymphoma-associated chromosomal translocation (LLA-CT) is much more frequent than subsequent neoplasia. Just like T(12;15)-carrying B-lymphocytes and plasma cells in mice, the malignant transformation of LLA-CT–bearing blood cells in humans may be a rare occurrence that requires several genetic and environmental cofactors to take place.
- 1 July 2008
- Published by Oxford University Press (OUP) in JNCI Monographs
- Vol. 2008 (39) , 37-40
Open AccessGenetic and Environmental Cofactors of Myc Translocations in Plasma Cell Tumor Development in Mice
Peritoneal plasmacytomagenesis in inbred BALB/c mice affords an experimental model system for the study of the mechanism by which naturally occurring Myc (c-myc) translocations collaborate with host susceptibility factors and environmental influences in tumor development. Mouse plasmacytoma is initiated in ∼80% of cases by a balanced chromosomal T(12;15)(Igh-Myc) translocation that results in a mode of Myc deregulation that renders the survival and outgrowth of the translocation-bearing tumor precursor exquisitely dependent upon factors provided by sustained inflammation (IL-6) and gut flora microbes. Tumor susceptibility genes of BALB/c, such as weak efficiency alleles of genes encoding p16Ink4a and Frap (mTOR), are also required for plasmacytoma, although the pathways linking these genes with deregulated Myc and the environment have not yet been elucidated. The findings in mouse plasmacytoma may be relevant for hematopoietic neoplasms in human beings, in which leukemia- and lymphoma-associated chromosomal translocation (LLA-CT) is much more frequent than subsequent neoplasia. Just like T(12;15)-carrying B-lymphocytes and plasma cells in mice, the malignant transformation of LLA-CT–bearing blood cells in humans may be a rare occurrence that requires several genetic and environmental cofactors to take place.
- 1 September 2006
- Published by Elsevier in DNA Repair
- Vol. 5 (9-10) , 1213-1224
Myc translocations in B cell and plasma cell neoplasms
- 1 September 2006
- Published by Elsevier in DNA Repair
- Vol. 5 (9-10) , 1213-1224
Myc translocations in B cell and plasma cell neoplasms
- Open Access
- 7 June 2006
- Published by Springer Nature in Molecular Cancer
- Vol. 5 (1) , 1-22
CDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms
Background: Gene-targeted iMycEμmice that carry a His6-tagged mouseMyc(c-myc)cDNA,MycHis, just 5' of the immunoglobulin heavy-chain enhancer, Eμ, are prone to B cell and plasma cell neoplasms, such as lymphoblastic B-cell lymphoma (LBL) and plasmacytoma (PCT). Cell lines derived from Myc-induced neoplasms of this sort may provide a good model system for the design and testing of new approaches to prevent and treat MYC-driven B cell and plasma cell neoplasms in human beings. To test this hypothesis, we used the LBL-derived cell line, iMycEμ-1, and the newly established PCT-derived cell line, iMycEμ-2, to evaluate the growth inhibitory and death inducing potency of the cancer drug candidate, CDDO-imidazolide (CDDO-Im).Methods: Morphological features and surface marker expression of iMycEμ-2 cells were evaluated using cytological methods and FACS, respectively. mRNA expression levels of the insertedMycHisand normalMycgenes were determined by allele-specific RT-PCR and qPCR. Myc protein was detected by immunoblotting. Cell cycle progression and apoptosis were analyzed by FACS. The expression of 384 "pathway" genes was assessed with the help of Superarray©cDNA macroarrays and verified, in part, by RT-PCR.Results: Sub-micromolar concentrations of CDDO-Im caused growth arrest and apoptosis in iMycEμ-1 and iMycEμ-2 cells. CDDO-Im-dependent growth inhibition and apoptosis were associated in both cell lines with the up-regulation of 30 genes involved in apoptosis, cell cycling, NFκB signaling, and stress and toxicity responses. Strongly induced (≥10 fold) were genes encoding caspase 14, heme oxygenase 1 (Hmox1), flavin-containing monooxygenase 4 (Fmo4), and three members of the cytochrome P450 subfamily 2 of mixed-function oxygenases (Cyp2a4, Cyp2b9, Cyp2c29). CDDO-Im-dependent gene induction coincided with a decrease in Myc protein.Conclusion: Growth arrest and killing of neoplastic mouse B cells and plasma cells by CDDO-Im, a closely related derivative of the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid, appears to be caused, in part, by drug-induced stress responses and reduction of Myc.
- 7 June 2006
- Published by Springer Nature in Molecular Cancer
- Vol. 5 (1) , 1-22
Open AccessCDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms
Background: Gene-targeted iMycEμmice that carry a His6-tagged mouseMyc(c-myc)cDNA,MycHis, just 5' of the immunoglobulin heavy-chain enhancer, Eμ, are prone to B cell and plasma cell neoplasms, such as lymphoblastic B-cell lymphoma (LBL) and plasmacytoma (PCT). Cell lines derived from Myc-induced neoplasms of this sort may provide a good model system for the design and testing of new approaches to prevent and treat MYC-driven B cell and plasma cell neoplasms in human beings. To test this hypothesis, we used the LBL-derived cell line, iMycEμ-1, and the newly established PCT-derived cell line, iMycEμ-2, to evaluate the growth inhibitory and death inducing potency of the cancer drug candidate, CDDO-imidazolide (CDDO-Im).Methods: Morphological features and surface marker expression of iMycEμ-2 cells were evaluated using cytological methods and FACS, respectively. mRNA expression levels of the insertedMycHisand normalMycgenes were determined by allele-specific RT-PCR and qPCR. Myc protein was detected by immunoblotting. Cell cycle progression and apoptosis were analyzed by FACS. The expression of 384 "pathway" genes was assessed with the help of Superarray©cDNA macroarrays and verified, in part, by RT-PCR.Results: Sub-micromolar concentrations of CDDO-Im caused growth arrest and apoptosis in iMycEμ-1 and iMycEμ-2 cells. CDDO-Im-dependent growth inhibition and apoptosis were associated in both cell lines with the up-regulation of 30 genes involved in apoptosis, cell cycling, NFκB signaling, and stress and toxicity responses. Strongly induced (≥10 fold) were genes encoding caspase 14, heme oxygenase 1 (Hmox1), flavin-containing monooxygenase 4 (Fmo4), and three members of the cytochrome P450 subfamily 2 of mixed-function oxygenases (Cyp2a4, Cyp2b9, Cyp2c29). CDDO-Im-dependent gene induction coincided with a decrease in Myc protein.Conclusion: Growth arrest and killing of neoplastic mouse B cells and plasma cells by CDDO-Im, a closely related derivative of the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid, appears to be caused, in part, by drug-induced stress responses and reduction of Myc.
- 15 February 2006
- Published by Wiley in The Journal of Pathology
- Vol. 209 (1) , 44-55
Plasma cell tumour progression in iMycEµ gene‐insertion mice
The authors have recently reported that gene‐targeted iMycEµ mice that carry a His6‐tagged mouse Myc cDNA, MycHis, just 5′ of the immunoglobulin heavy‐chain enhancer, Eµ, are prone to ‘spontaneous’ neoplasms of the B‐lymphocyte lineage. The present study has used histological, immunohistochemical, and molecular genetic methods to investigate a subset of these neoplasms referred to as extraosseous plasmacytomas (PCTs). It is shown that 20.8% (20/96) of tumour‐bearing iMycEµ mice on a mixed genetic background of segregating C57BL/6 and 129/SvJ alleles develop PCT by 500 days. The MycHis‐induced PCTs produced monoclonal immunoglobulin and developed in the gut‐associated lymphoid tissue (GALT), particularly the mesenteric node and Peyer's patches. The PCTs overexpressed MycHis, at the expense of normal Myc, and exhibited gene expression changes on cDNA macroarrays that were consistent with MycHis‐driven neoplasia. Surprisingly, in one of three PCT‐derived cell lines, MycHis was ‘replaced’ by a naturally occurring T(12;15) translocation, which changed the mode of Myc deregulation from gene insertion (MycHis transgene) to chromosomal translocation (juxtaposition of normal Myc to the immunoglobulin heavy‐chain locus Igh). These findings provide evidence that recreation of the mouse PCT‐associated T(12;15)(IghEµ ‐Myc) translocation by gene insertion in mice results in the predictable development of PCTs in approximately one‐fifth of the tumour‐bearing mice. MycHis‐driven PCTs recapitulate aspects of human plasma cell neoplasms, for which relatively few models exist in mice. For example, PCT development in the iMycEµ mice may provide a good system to study the mechanism by which human MYC facilitates the progression of plasma cell myeloma (multiple myeloma) in humans. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- 15 February 2006
- Published by Wiley in The Journal of Pathology
- Vol. 209 (1) , 44-55
Plasma cell tumour progression in iMycEµ gene‐insertion mice
The authors have recently reported that gene‐targeted iMycEµ mice that carry a His6‐tagged mouse Myc cDNA, MycHis, just 5′ of the immunoglobulin heavy‐chain enhancer, Eµ, are prone to ‘spontaneous’ neoplasms of the B‐lymphocyte lineage. The present study has used histological, immunohistochemical, and molecular genetic methods to investigate a subset of these neoplasms referred to as extraosseous plasmacytomas (PCTs). It is shown that 20.8% (20/96) of tumour‐bearing iMycEµ mice on a mixed genetic background of segregating C57BL/6 and 129/SvJ alleles develop PCT by 500 days. The MycHis‐induced PCTs produced monoclonal immunoglobulin and developed in the gut‐associated lymphoid tissue (GALT), particularly the mesenteric node and Peyer's patches. The PCTs overexpressed MycHis, at the expense of normal Myc, and exhibited gene expression changes on cDNA macroarrays that were consistent with MycHis‐driven neoplasia. Surprisingly, in one of three PCT‐derived cell lines, MycHis was ‘replaced’ by a naturally occurring T(12;15) translocation, which changed the mode of Myc deregulation from gene insertion (MycHis transgene) to chromosomal translocation (juxtaposition of normal Myc to the immunoglobulin heavy‐chain locus Igh). These findings provide evidence that recreation of the mouse PCT‐associated T(12;15)(IghEµ ‐Myc) translocation by gene insertion in mice results in the predictable development of PCTs in approximately one‐fifth of the tumour‐bearing mice. MycHis‐driven PCTs recapitulate aspects of human plasma cell neoplasms, for which relatively few models exist in mice. For example, PCT development in the iMycEµ mice may provide a good system to study the mechanism by which human MYC facilitates the progression of plasma cell myeloma (multiple myeloma) in humans. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- Open Access
- 9 November 2005
- Published by Springer Nature in Molecular Cancer
- Vol. 4 (1) , 1-40
Molecular and cytological features of the mouse B-cell lymphoma line iMycEμ-1
Background: Myc-induced lymphoblastic B-cell lymphoma (LBL) in iMycEμ mice may provide a model system for the study of the mechanism by which human MYC facilitates the initiation and progression of B cell and plasma cell neoplasms in human beings. We have recently shown that gene-targeted iMycEμ mice that carry a His6-tagged mouse Myc cDNA, Myc His, just 5' of the immunoglobulin heavy-chain enhancer, Eμ, are prone to B cell and plasma cell tumors. The predominant tumor (~50%) that arose in the iMycEμ mice on the mixed genetic background of segregating C57BL/6 and 129/SvJ alleles was LBL. The purpose of this study was to establish and characterize a cell line, designated iMycEμ-1, for the in-depth evaluation of LBL in vitro. Methods: The morphological features and the surface marker expression profile of the iMycEμ-1 cells were evaluated using cytological methods and FACS, respectively. The cytogenetic make-up of the iMycEμ-1 cells was assessed by spectral karyotyping (SKY). The expression of the inserted Myc His gene was determined using RT-PCR and qPCR. Clonotypic immunoglobulin gene arrangements were detected by Southern blotting. The global gene expression program of the iMycEμ-1 cells and the expression of 768 "pathway" genes were determined with the help of the Mouse Lymphochip© and Superarray© cDNA micro- and macroarrays, respectively. Array results were verified, in part, by RT-PCR and qPCR. Results: Consistent with their derivation from LBL, the iMycEμ-1 cells were found to be neoplastic IgMhighIgDlow lymphoblasts that expressed typical B-cell surface markers including CD40, CD54 (ICAM-1), CD80 (B7-1) and CD86 (B7-2). The iMycEμ-1 cells harbored a reciprocal T(9;11) and three non-reciprocal chromosomal translocations, over-expressed Myc His at the expense of normal Myc, and exhibited gene expression changes on Mouse Lymphochip© microarrays that were consistent with Myc His-driven B-cell neoplasia. Upon comparison to normal B cells using eight different Superarray© cDNA macroarrays, the iMycEμ-1 cells showed the highest number of changes on the NFκB array. Conclusion: The iMycEμ-1 cells may provide a uniquely useful model system to study the growth and survival requirements of Myc-driven mouse LBL in vitro.
- 9 November 2005
- Published by Springer Nature in Molecular Cancer
- Vol. 4 (1) , 1-40
Open AccessMolecular and cytological features of the mouse B-cell lymphoma line iMycEμ-1
Background: Myc-induced lymphoblastic B-cell lymphoma (LBL) in iMycEμ mice may provide a model system for the study of the mechanism by which human MYC facilitates the initiation and progression of B cell and plasma cell neoplasms in human beings. We have recently shown that gene-targeted iMycEμ mice that carry a His6-tagged mouse Myc cDNA, Myc His, just 5' of the immunoglobulin heavy-chain enhancer, Eμ, are prone to B cell and plasma cell tumors. The predominant tumor (~50%) that arose in the iMycEμ mice on the mixed genetic background of segregating C57BL/6 and 129/SvJ alleles was LBL. The purpose of this study was to establish and characterize a cell line, designated iMycEμ-1, for the in-depth evaluation of LBL in vitro. Methods: The morphological features and the surface marker expression profile of the iMycEμ-1 cells were evaluated using cytological methods and FACS, respectively. The cytogenetic make-up of the iMycEμ-1 cells was assessed by spectral karyotyping (SKY). The expression of the inserted Myc His gene was determined using RT-PCR and qPCR. Clonotypic immunoglobulin gene arrangements were detected by Southern blotting. The global gene expression program of the iMycEμ-1 cells and the expression of 768 "pathway" genes were determined with the help of the Mouse Lymphochip© and Superarray© cDNA micro- and macroarrays, respectively. Array results were verified, in part, by RT-PCR and qPCR. Results: Consistent with their derivation from LBL, the iMycEμ-1 cells were found to be neoplastic IgMhighIgDlow lymphoblasts that expressed typical B-cell surface markers including CD40, CD54 (ICAM-1), CD80 (B7-1) and CD86 (B7-2). The iMycEμ-1 cells harbored a reciprocal T(9;11) and three non-reciprocal chromosomal translocations, over-expressed Myc His at the expense of normal Myc, and exhibited gene expression changes on Mouse Lymphochip© microarrays that were consistent with Myc His-driven B-cell neoplasia. Upon comparison to normal B cells using eight different Superarray© cDNA macroarrays, the iMycEμ-1 cells showed the highest number of changes on the NFκB array. Conclusion: The iMycEμ-1 cells may provide a uniquely useful model system to study the growth and survival requirements of Myc-driven mouse LBL in vitro.
- 21 March 2005
- Published by Springer Nature in Oncogene
- Vol. 24 (22) , 3541-3543
Uncovering MYC's full oncogenic potential in the hematopoietic system
MYC is an important oncogene in hematopoietic neoplasms in humans, yet the mechanism by which MYC induces the malignant transformation of blood cells has remained elusive. Postulating that mouse models of deregulated MYC expression may be helpful for advancing our understanding of MYC-induced hematopoietic malignancies, Suzanne Cory and her associates took advantage of the Vav promoter to express MYC throughout the hematopoietic system in transgenic mice. They report that the newly developed strain, referred to as VavP-MYC17, is prone to mature T-cell lymphomas (for which few good mouse models exist). They further show that VavP-MYC17 mice that are devoid of mature T cells (and B cells) because of genetic deficiency in Rag1 recombinase develop neoplasms of three distinct blood cell lineages: pre-T cells, pro-B cells, and macrophages. These findings establish that VavP-driven MYC has broad oncogenic potential in the hematopoietic compartment and prompts new views of the cellular assaults of deregulated MYC on hematopoietic stem and early progenitor cells.
- 21 March 2005
- Published by Springer Nature in Oncogene
- Vol. 24 (22) , 3541-3543
Uncovering MYC's full oncogenic potential in the hematopoietic system
MYC is an important oncogene in hematopoietic neoplasms in humans, yet the mechanism by which MYC induces the malignant transformation of blood cells has remained elusive. Postulating that mouse models of deregulated MYC expression may be helpful for advancing our understanding of MYC-induced hematopoietic malignancies, Suzanne Cory and her associates took advantage of the Vav promoter to express MYC throughout the hematopoietic system in transgenic mice. They report that the newly developed strain, referred to as VavP-MYC17, is prone to mature T-cell lymphomas (for which few good mouse models exist). They further show that VavP-MYC17 mice that are devoid of mature T cells (and B cells) because of genetic deficiency in Rag1 recombinase develop neoplasms of three distinct blood cell lineages: pre-T cells, pro-B cells, and macrophages. These findings establish that VavP-driven MYC has broad oncogenic potential in the hematopoietic compartment and prompts new views of the cellular assaults of deregulated MYC on hematopoietic stem and early progenitor cells.
- 11 January 2005
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 42 (4) , 416-426
Location ofMyc,Igh, andIgk on Robertsonian fusion chromosomes is inconsequential forMyc translocations and plasmacytoma development in mice, but Rb(6.15)-carrying tumors preferIgk-Myc inversions over translocations
- 11 January 2005
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 42 (4) , 416-426
Location ofMyc,Igh, andIgk on Robertsonian fusion chromosomes is inconsequential forMyc translocations and plasmacytoma development in mice, but Rb(6.15)-carrying tumors preferIgk-Myc inversions over translocations
- 15 June 2004
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 113 (12) , 1763-1773
Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice
Deregulated expression of both Myc and Bcl-XL are consistent features of human plasma cell neoplasms (PCNs). To investigate whether targeted expression of Myc and Bcl-XL in mouse plasma cells might lead to an improved model of human PCN, we generated Myc transgenics by inserting a single-copy histidine-tagged mouse Myc gene, MycHis, into the mouse Ig heavy-chain Cα locus. We also generated Bcl-XL transgenic mice that contain a multicopy Flag-tagged mouse Bcl-xFlag transgene driven by the mouse Ig κ light-chain 3′ enhancer. Single-transgenic Bcl-XL mice remained tumor free by 380 days of age, whereas single-transgenic Myc mice developed B cell tumors infrequently (4 of 43, 9.3%). In contrast, double-transgenic Myc/Bcl-XL mice developed plasma cell tumors with short onset (135 days on average) and full penetrance (100% tumor incidence). These tumors produced monoclonal Ig, infiltrated the bone marrow, and contained elevated amounts of MycHis and Bcl-XLFlag proteins compared with the plasma cells that accumulated in large numbers in young tumor-free Myc/Bcl-XL mice. Our findings demonstrate that the enforced expression of Myc and Bcl-XL by Ig enhancers with peak activity in plasma cells generates a mouse model of human PCN that recapitulates some features of human multiple myeloma.
- 15 June 2004
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 113 (12) , 1763-1773
Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice
Deregulated expression of both Myc and Bcl-XL are consistent features of human plasma cell neoplasms (PCNs). To investigate whether targeted expression of Myc and Bcl-XL in mouse plasma cells might lead to an improved model of human PCN, we generated Myc transgenics by inserting a single-copy histidine-tagged mouse Myc gene, MycHis, into the mouse Ig heavy-chain Cα locus. We also generated Bcl-XL transgenic mice that contain a multicopy Flag-tagged mouse Bcl-xFlag transgene driven by the mouse Ig κ light-chain 3′ enhancer. Single-transgenic Bcl-XL mice remained tumor free by 380 days of age, whereas single-transgenic Myc mice developed B cell tumors infrequently (4 of 43, 9.3%). In contrast, double-transgenic Myc/Bcl-XL mice developed plasma cell tumors with short onset (135 days on average) and full penetrance (100% tumor incidence). These tumors produced monoclonal Ig, infiltrated the bone marrow, and contained elevated amounts of MycHis and Bcl-XLFlag proteins compared with the plasma cells that accumulated in large numbers in young tumor-free Myc/Bcl-XL mice. Our findings demonstrate that the enforced expression of Myc and Bcl-XL by Ig enhancers with peak activity in plasma cells generates a mouse model of human PCN that recapitulates some features of human multiple myeloma.
- 8 May 2003
- Published by Springer Nature in Oncogene
- Vol. 22 (18) , 2842-2850
Eμ/Sμ transposition into Myc is sometimes a precursor for T(12;15) translocation in mouse B cells
Misguided immunoglobulin (Ig) class switch recombination (CSR) has been implicated in the origin of Myc-activating chromosomal translocations, T(12;15), in BALB/c mouse plasmacytomas (PCTs). CSR has also been involved in the progression of T(12;15); for example, the approximation of Myc to the 3'-C enhancer. This study provides evidence for an additional mechanism by which aberrant CSR may facilitate T(12;15): transposition of Ig heavy-chain (IgH) sequences to Myc. Five IgH transposons containing the intronic heavy-chain enhancer, E, and a truncated switch region, S, were found in the first intron of Myc in lymph node cells of IL-6 transgenic BALB/c mice. In two cases E/S transposition primed Myc to get involved in apparent trans-chromosomal CSR to C1, presumably leading to T(12;15). Translocations preceded by E/S transposition can sometimes be distinguished from de novo translocations by molecular fingerprints in translocation breakpoint regions (Ig switch region [S] inversions and unusual gene orders in composite S regions). The presence of such fingerprints in some PCTs suggests that the tumors sometimes evolve from transposition-bearing precursors. We propose that E/S transposition to Myc may facilitate plasmacytomagenesis by sensitizing Myc to undergo T(12;15) translocation. T(12;15), in turn, juxtaposes Myc to the 3'-C enhancer, which appears to be required for deregulating Myc in a manner that is conducive to PCT development.
- 8 May 2003
- Published by Springer Nature in Oncogene
- Vol. 22 (18) , 2842-2850
Eμ/Sμ transposition into Myc is sometimes a precursor for T(12;15) translocation in mouse B cells
Misguided immunoglobulin (Ig) class switch recombination (CSR) has been implicated in the origin of Myc-activating chromosomal translocations, T(12;15), in BALB/c mouse plasmacytomas (PCTs). CSR has also been involved in the progression of T(12;15); for example, the approximation of Myc to the 3'-C enhancer. This study provides evidence for an additional mechanism by which aberrant CSR may facilitate T(12;15): transposition of Ig heavy-chain (IgH) sequences to Myc. Five IgH transposons containing the intronic heavy-chain enhancer, E, and a truncated switch region, S, were found in the first intron of Myc in lymph node cells of IL-6 transgenic BALB/c mice. In two cases E/S transposition primed Myc to get involved in apparent trans-chromosomal CSR to C1, presumably leading to T(12;15). Translocations preceded by E/S transposition can sometimes be distinguished from de novo translocations by molecular fingerprints in translocation breakpoint regions (Ig switch region [S] inversions and unusual gene orders in composite S regions). The presence of such fingerprints in some PCTs suggests that the tumors sometimes evolve from transposition-bearing precursors. We propose that E/S transposition to Myc may facilitate plasmacytomagenesis by sensitizing Myc to undergo T(12;15) translocation. T(12;15), in turn, juxtaposes Myc to the 3'-C enhancer, which appears to be required for deregulating Myc in a manner that is conducive to PCT development.
- 23 January 2003
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 36 (3) , 211-223
Lymphoma‐ and leukemia‐associated chromosomal translocations in healthy individuals
Chromosomal translocations (CTs) are hallmark mutations of hematopoietic malignancy that result in the deregulated expression of oncogenes or the generation of novel fusion genes. The polymerase chain reaction (PCR) can be used to detect illegitimate recombinations of genomic DNA sequences as a more sensitive assay than cytogenetics for determining the presence of CTs. Both direct DNA‐PCR and reverse transcriptase‐PCR were used to examine healthy individuals for lymphoma‐ and leukemia‐associated CTs. Two oncogene‐activating CTs [t(14;18)(q32;q21) and t(8;14)(q24;q32)] and one fusion‐gene CT [t(2;5)(p23;q35)] from lymphomas and five fusion‐gene CTs from leukemia [t(9;22)(q34;q11), t(4;11)(q21;q23), t(15;17)(q22;q11), t(12;21)(p13;q22), t(8;21)(q22;q22)] were detected in such studies. The biological implication is that CTs associated with malignant tumors may also be found in cells that are not neoplastic. CTs are characteristic attributes of neoplastic clones but are by themselves insufficient to cause malignant transformation. A better understanding of the special biology of non‐neoplastic CT‐bearing cells will provide insight into their putative role as tumor precursors. Prospective epidemiological studies are needed to determine whether such cells in healthy individuals may, in some instances, become clonogenic founders of lymphoma or leukemia.
- 23 January 2003
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 36 (3) , 211-223
Lymphoma‐ and leukemia‐associated chromosomal translocations in healthy individuals
Chromosomal translocations (CTs) are hallmark mutations of hematopoietic malignancy that result in the deregulated expression of oncogenes or the generation of novel fusion genes. The polymerase chain reaction (PCR) can be used to detect illegitimate recombinations of genomic DNA sequences as a more sensitive assay than cytogenetics for determining the presence of CTs. Both direct DNA‐PCR and reverse transcriptase‐PCR were used to examine healthy individuals for lymphoma‐ and leukemia‐associated CTs. Two oncogene‐activating CTs [t(14;18)(q32;q21) and t(8;14)(q24;q32)] and one fusion‐gene CT [t(2;5)(p23;q35)] from lymphomas and five fusion‐gene CTs from leukemia [t(9;22)(q34;q11), t(4;11)(q21;q23), t(15;17)(q22;q11), t(12;21)(p13;q22), t(8;21)(q22;q22)] were detected in such studies. The biological implication is that CTs associated with malignant tumors may also be found in cells that are not neoplastic. CTs are characteristic attributes of neoplastic clones but are by themselves insufficient to cause malignant transformation. A better understanding of the special biology of non‐neoplastic CT‐bearing cells will provide insight into their putative role as tumor precursors. Prospective epidemiological studies are needed to determine whether such cells in healthy individuals may, in some instances, become clonogenic founders of lymphoma or leukemia.